180 related articles for article (PubMed ID: 37460674)
1. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
[TBL] [Abstract][Full Text] [Related]
2. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
3. MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
Zeineldin M; Federico S; Chen X; Fan Y; Xu B; Stewart E; Zhou X; Jeon J; Griffiths L; Nguyen R; Norrie J; Easton J; Mulder H; Yergeau D; Liu Y; Wu J; Van Ryn C; Naranjo A; Hogarty MD; Kamiński MM; Valentine M; Pruett-Miller SM; Pappo A; Zhang J; Clay MR; Bahrami A; Vogel P; Lee S; Shelat A; Sarthy JF; Meers MP; George RE; Mardis ER; Wilson RK; Henikoff S; Downing JR; Dyer MA
Nat Commun; 2020 Feb; 11(1):913. PubMed ID: 32060267
[TBL] [Abstract][Full Text] [Related]
4. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
Akter J; Kamijo T
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
[TBL] [Abstract][Full Text] [Related]
5. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
[TBL] [Abstract][Full Text] [Related]
6. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
Nakazawa A
Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
[TBL] [Abstract][Full Text] [Related]
7. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.
Duan XF; Zhao Q
J Pediatr Hematol Oncol; 2018 Jan; 40(1):1-6. PubMed ID: 28452859
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
[TBL] [Abstract][Full Text] [Related]
9. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
10. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
[TBL] [Abstract][Full Text] [Related]
11. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
12. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J
Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703
[TBL] [Abstract][Full Text] [Related]
13. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
14. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
16. ONC201 Suppresses Neuroblastoma Growth by Interrupting Mitochondrial Function and Reactivating Nuclear ATRX Expression While Decreasing MYCN.
Wu JC; Huang CC; Wang PW; Chen TY; Hsu WM; Chuang JH; Chuang HC
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675163
[TBL] [Abstract][Full Text] [Related]
17. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.
Valentijn LJ; Koster J; Zwijnenburg DA; Hasselt NE; van Sluis P; Volckmann R; van Noesel MM; George RE; Tytgat GA; Molenaar JJ; Versteeg R
Nat Genet; 2015 Dec; 47(12):1411-4. PubMed ID: 26523776
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
19. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
[TBL] [Abstract][Full Text] [Related]
20. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
